Literature DB >> 23836884

Huntingtin-interacting protein 1 phosphorylation by receptor tyrosine kinases.

Heather M Ames1, Anmin A Wang, Alanna Coughran, Kristen Evaul, Sha Huang, Chiron W Graves, Abigail A Soyombo, Theodora S Ross.   

Abstract

Huntingtin-interacting protein 1 (HIP1) binds inositol lipids, clathrin, actin, and receptor tyrosine kinases (RTKs). HIP1 is elevated in many tumors, and its expression is prognostic in prostate cancer. HIP1 overexpression increases levels of the RTK epidermal growth factor receptor (EGFR) and transforms fibroblasts. Here we report that HIP1 is tyrosine phosphorylated in the presence of EGFR and platelet-derived growth factor β receptor (PDGFβR) as well as the oncogenic derivatives EGFRvIII, HIP1/PDGFβR (H/P), and TEL/PDGFβR (T/P). We identified a four-tyrosine "HIP1 phosphorylation motif" (HPM) in the N-terminal region of HIP1 that is required for phosphorylation mediated by both EGFR and PDGFβR but not by the oncoproteins H/P and T/P. We also identified a tyrosine residue (Y152) within the HPM motif of HIP1 that inhibits HIP1 tyrosine phosphorylation. The HPM tyrosines are conserved in HIP1's only known mammalian relative, HIP1-related protein (HIP1r), and are also required for HIP1r phosphorylation. Tyrosine-to-phenylalanine point mutations in the HPM of HIP1 result in proapoptotic activity, indicating that an intact HPM may be necessary for HIP1's role in cellular survival. These data suggest that phosphorylation of HIP1 by RTKs in an N-terminal region contributes to the promotion of cellular survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836884      PMCID: PMC3753876          DOI: 10.1128/MCB.00473-13

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis.

Authors:  S Waelter; E Scherzinger; R Hasenbank; E Nordhoff; R Lurz; H Goehler; C Gauss; K Sathasivam; G P Bates; H Lehrach; E E Wanker
Journal:  Hum Mol Genet       Date:  2001-08-15       Impact factor: 6.150

3.  Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins.

Authors:  S K Mishra; N R Agostinelli; T J Brett; I Mizukami; T S Ross; L M Traub
Journal:  J Biol Chem       Date:  2001-09-27       Impact factor: 5.157

4.  HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2.

Authors:  M Metzler; V Legendre-Guillemin; L Gan; V Chopra; A Kwok; P S McPherson; M R Hayden
Journal:  J Biol Chem       Date:  2001-08-21       Impact factor: 5.157

5.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

6.  Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.

Authors:  Dinesh S Rao; Teresa S Hyun; Priti D Kumar; Ikuko F Mizukami; Mark A Rubin; Peter C Lucas; Martin G Sanda; Theodora S Ross
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

7.  Huntingtin interacting protein 1 Is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors.

Authors:  D S Rao; J C Chang; P D Kumar; I Mizukami; G M Smithson; S V Bradley; A F Parlow; T S Ross
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking.

Authors:  Martina Metzler; Bo Li; Lu Gan; John Georgiou; Claire-Anne Gutekunst; Yushan Wang; Enrique Torre; Rebecca S Devon; Rosemary Oh; Valerie Legendre-Guillemin; Mark Rich; Christine Alvarez; Marina Gertsenstein; Peter S McPherson; Andras Nagy; Yu Tian Wang; John C Roder; Lynn A Raymond; Michael R Hayden
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

9.  Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes.

Authors:  M G Ford; B M Pearse; M K Higgins; Y Vallis; D J Owen; A Gibson; C R Hopkins; P R Evans; H T McMahon
Journal:  Science       Date:  2001-02-09       Impact factor: 47.728

10.  Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells.

Authors:  Dinesh S Rao; Sarah V Bradley; Priti D Kumar; Teresa S Hyun; Djenann Saint-Dic; Katherine Oravecz-Wilson; Celina G Kleer; Theodora S Ross
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

View more
  5 in total

1.  Biologically active substances-enriched diet regulates gonadotrope cell activation pathway in liver of adult and old rats.

Authors:  Hanna Oszkiel; Jacek Wilczak; Michał Jank
Journal:  Genes Nutr       Date:  2014-08-26       Impact factor: 5.523

2.  Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function.

Authors:  Victoria E Mgbemena; Robert A J Signer; Ranjula Wijayatunge; Travis Laxson; Sean J Morrison; Theodora S Ross
Journal:  Cell Rep       Date:  2017-01-24       Impact factor: 9.423

3.  Disabled-2 is a negative immune regulator of lipopolysaccharide-stimulated Toll-like receptor 4 internalization and signaling.

Authors:  Wei-Shan Hung; Pin Ling; Ju-Chien Cheng; Shy-Shin Chang; Ching-Ping Tseng
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

4.  Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.

Authors:  Jinghan Wang; Mengxia Yu; Qi Guo; Qiuling Ma; Chao Hu; Zhixin Ma; Xiufeng Yin; Xia Li; Yungui Wang; Hanzhang Pan; Dongmei Wang; Jiansong Huang; Haitao Meng; Hongyan Tong; Wenbin Qian; Jie Jin
Journal:  Sci Rep       Date:  2017-04-28       Impact factor: 4.379

5.  Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.

Authors:  S T Philips; Z L Hildenbrand; K I Oravecz-Wilson; S B Foley; V E Mgbemena; T S Ross
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.